Drug interactions with lipid-lowering drugs: Mechanisr

Clinical Pharmacology and Therapeutics
80, 565-581
DOI: 10.1016/j.clpt.2006.09.003

Citation Report

#	Article	IF	Citations
1	Cholesterol-Lowering Drugs And Alzheimerâ€™S Disease. Future Lipidology, 2007, 2, 423-432.	0.5	18
2	Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2007, 29, 687-710.	1.0	317
3	Transporter-mediated uptake into cellular compartments. Xenobiotica, 2007, 37, 1171-1195.	0.5	38
4	Hypertriglyceridemia and cardiovascular risk reduction. Clinical Therapeutics, 2007, 29, 763-777.	1.1	113
5	HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infectious Diseases, The, 2007, 7, 787-796.	4.6	125
6	Simvastatin: present and future perspectives. Expert Opinion on Pharmacotherapy, 2007, 8, 2159-2127.	0.9	20
7	Clopidogrelâ€“Statin Interaction. Journal of the American College of Cardiology, 2007, 50, 296-298.	1.2	50
8	Genetic variation in thyroid hormone transporters. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 339-350.	2.2	28
9	Role of OATP transporters in the disposition of drugs. Pharmacogenomics, 2007, 8, 787-802.	0.6	241
10	Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. Biopharmaceutics and Drug Disposition, 2007, 28, 403-407.	1.1	7
11	The new acylâ€CoA cholesterol acyltransferase inhibitor SMPâ€797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems. Biopharmaceutics and Drug Disposition, 2007, 28, 517-525.	1.1	6
13	Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin. Clinical Pharmacology and Therapeutics, 2007, 82, 726-733.	2.3	381
14	New lifestyle drugs and somatoform disorders in dermatology. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 141-149.	1.3	16
15	Identification of drugs that interact with herbs in drug development. Drug Discovery Today, 2007, 12, 664-673.	3.2	138
16	The Cholesterol Paradox in Heart Failure. Congestive Heart Failure, 2007, 13, 336-341.	2.0	43
17	Combination therapy of dyslipidemia. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 249-258.	0.4	8
18	Effect of Silymarin Supplement on the Pharmacokinetics of Rosuvastatin. Pharmaceutical Research, 2008, 25, 1807-1814.	1.7	57
19	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry, 2008, 392, 1093-1108.	1.9	510

#	Article	IF	Citations
20	Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. European Journal of Clinical Pharmacology, 2008, 64, 445-449.	0.8	36
21	Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. European Journal of Clinical Pharmacology, 2008, 64, 1135-1136.	0.8	12
23	Global analysis of genetic variation inÂSLCO1B1. Pharmacogenomics, 2008, 9, 19-33.	0.6	168
24	Mechanism-Based Inactivation of Human Cytochromes P450s: Experimental Characterization, Reactive Intermediates, and Clinical Implications. Chemical Research in Toxicology, 2008, 21, 189-205.	1.7	156
25	Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats¹. Acta Pharmacologica Sinica, 2008, 29, 1247-1252.	2.8	17
26	ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin. Clinical Pharmacology and Therapeutics, 2008, 84, 457-461.	2.3	134
27	Effects of Pravastatin on Obesity, Diabetes, and Adiponectin in Dietâ€induced Obese Mice. Obesity, 2008, 16, 2068-2073.	1.5	14
28	Prodrugs: design and clinical applications. Nature Reviews Drug Discovery, 2008, 7, 255-270.	21.5	1,253
29	Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 Inhibitors. Drug Safety, 2008, 31, 587-596.	1.4	37
30	Determinants of Steady-State Torasemide Pharmacokinetics. Clinical Pharmacokinetics, 2008, 47, 323-332.	1.6	37
31	Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. Clinical Pharmacokinetics, 2008, 47, 463-474.	1.6	177
33	Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. Journal of Clinical Lipidology, 2008, 2, 453-463.	0.6	39
34	PhRMA White Paper on ADME Pharmacogenomics. Journal of Clinical Pharmacology, 2008, 48, 849-889.	1.0	62
35	New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process. Journal of Clinical Pharmacology, 2008, 48, 662-670.	1.0	333
36	Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicology in Vitro, 2008, 22, 96-105.	1.1	19
37	New insights into mechanisms of statin-associated myotoxicity. Current Opinion in Pharmacology, 2008, 8, 333-338.	1.7	144
38	Rhabdomyolysis and pancreatitis associated with coadministration of danazol 600 mg/d and lovastatin 40 mg/d. Clinical Therapeutics, 2008, 30, 1330-1335.	1.1	16
39	Neuromuscular Complications of Statins. Physical Medicine and Rehabilitation Clinics of North America, 2008, 19, 47-59.	0.7	17

#	Article	IF	Citations
40	Statin Adverse Effects. American Journal of Cardiovascular Drugs, 2008, 8, 373-418.	1.0	564
41	Drugâ€“drug interaction with statins. Expert Review of Clinical Pharmacology, 2008, 1, 105-113.	1.3	24
42	Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters. Diabetes, 2008, 57, 1463-1469.	0.3	111
43	An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 287-304.	1.5	18
44	Management of Cardiovascular Disease in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 491-504.	2.2	101
45	Unraveling Pleiotropic Effects Of Statins. Circulation Research, 2008, 103, 334-336.	2.0	33
46	Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 570-578.	0.9	143
47	Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics, 2008, 9, 1133-1142.	0.6	22
48	Genetic determinants of statin-associated myopathy. Personalized Medicine, 2008, 5, 481-494.	0.8	6
49	Emerging lipid-lowering drugs: squalene synthase inhibitors. Expert Opinion on Emerging Drugs, 2008, 13, 309-322.	1.0	22
51	Drug interactions between statins and antiretroviral agents. Current Opinion in HIV and AIDS, 2008, 3, 247-251.	1.5	7
52	Statinâ€“Drug Interactions. Cardiology in Review, 2008, 16, 205-212.	0.6	27
53	Successful Boric Acid Treatment of Aspergillus niger Infection in an Exenterated Orbit. Ophthalmic Plastic and Reconstructive Surgery, 2008, 24, 79-81.	0.4	8
54	High Speed Clinical Data Retrieval System with Event Time Sequence Feature. Methods of Information in Medicine, 2008, 47, 560-568.	0.7	19
55	Lipid Abnormalities in Patients Infected With HumanImmunodeficiency Virus. Endocrine Practice, 2008, 14, 492-500.	1.1	7
56	Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vascular Health and Risk Management, 2008, 5, 31.	1.0	10
57	Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vascular Health and Risk Management, 2009, 5, 343.	1.0	26
58	Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vascular Health and Risk Management, 2009, 5, 921.	1.0	43

#	Article	IF	Citations
59	Myopathy with Concurrent Tadalafil and Simvastatin. Case Reports in Medicine, 2009, 2009, 1-3.	0.3	1
60	Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease. Current Pharmacogenomics and Personalized Medicine, 2009, 7, 1-26.	0.2	18
61	Role of membrane transporters in the safety profile of drugs. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1369-1383.	1.5	16
62	Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers. Journal of Clinical Pharmacology, 2009, 49, 568-573.	1.0	15
63	ABTâ€335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans. Journal of Clinical Pharmacology, 2009, 49, 63-71.	1.0	24
64	Statins. , 2009, , 253-280.		5
65	Antimicrobial and Immunomodulatory Attributes of Statins: Relevance in Solidâ€Organ Transplant Recipients. Clinical Infectious Diseases, 2009, 48, 745-755.	2.9	56
66	Does Simvastatin Cause More Myotoxicity Compared with Other Statins?. Annals of Pharmacotherapy, 2009, 43, 2012-2020.	0.9	44
67	Towards companion diagnostics for the management of statin therapy. Expert Opinion on Medical Diagnostics, 2009, 3, 659-671.	1.6	0
68	Lifestyle Drugs in Old Age â€“ A Mini-Review. Gerontology, 2009, 55, 13-20.	1.4	1
69	IMPROVING THE PREDICTION OF PHARMACOGENES USING TEXT-DERIVED DRUG-GENE RELATIONSHIPS. , 2009, , 305-314.		22
70	Pitavastatin Fails to Lower Serum Lipid Levels or Inhibit Gastric Carcinogenesis in Helicobacter pyloriâ€“Infected Rodent Models. Cancer Prevention Research, 2009, 2, 751-758.	0.7	10
71	Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics, 2009, 10, 1743-1751.	0.6	32
72	Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs. Side Effects of Drugs Annual, 2009, 31, 619-646.	0.6	0
73	Narrative Review: Statin-Related Myopathy. Annals of Internal Medicine, 2009, 150, 858.	2.0	369
74	Drug Interaction Potential of 2-((3,4-Dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the Novel Nonstatin-Type Cholesterol-Lowering Agent. Drug Metabolism and Disposition, 2009, 37, 375-385.	1.7	21
75	Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction. Pharmacotherapy, 2009, 29, 352-356.	1.2	35
76	A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clinical Therapeutics, 2009, 31, 586-599.	1.1	24

#	Article	IF	Citations
77	Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. European Journal of Pharmaceutical Sciences, 2009, 37, 126-132.	1.9	33
78	Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. European Journal of Pharmaceutical Sciences, 2009, 38, 519-524.	1.9	30
80	N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a â€œchemical knock-out equivalentâ€•to assess the impact of efflux transporters on oral drug absorption in the rat. Journal of Pharmaceutical Sciences, 2009, 98, 4914-4927.	1.6	24
81	SFINXâ€”a drug-drug interaction database designed for clinical decision support systems. European Journal of Clinical Pharmacology, 2009, 65, 627-633.	0.8	124
82	Coâ€•medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. British Journal of Clinical Pharmacology, 2009, 67, 234-241.	1.1	17
83	No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. British Journal of Clinical Pharmacology, 2009, 68, 207-213.	1.1	52
84	Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. British Journal of Clinical Pharmacology, 2009, 68, 427-434.	1.1	48
85	ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin. Clinical Pharmacology and Therapeutics, 2009, 86, 197-203.	2.3	365
86	Verapamil for Cluster Headache. Clinical Pharmacology and Possible Mode of Action. Headache, 2009, 49, 117-125.	1.8	63
87	Impact of OATP transporters on pharmacokinetics. British Journal of Pharmacology, 2009, 158, 693-705.	2.7	783
88	Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. Pharmacogenomics, 2009, 10, 1007-1016.	0.6	13
89	In vitroevidence for the role of OATP and OCT uptake transporters in drugâ€“drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 489-500.	1.5	71
90	A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling. Clinical Pharmacokinetics, 2009, 48, 653-666.	1.6	38
91	Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. Endocrinology and Metabolism Clinics of North America, 2009, 38, 79-97.	1.2	84
92	Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Medicine, 2009, 1, 10.	3.6	33
93	Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics, 2009, 10, 1017-1024.	0.6	41
94	Immunotherapy in Elderly Transplant Recipients. Drugs and Aging, 2009, 26, 715-737.	1.3	68
95	Careful individualized therapy improves the therapeutic efficacy of statins in patients with coronary heart disease. Drugs and Therapy Perspectives, 2009, 25, 12-15.	0.3	0

#	Article	IF	Citations
96	In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Current Medical Research and Opinion, 2009, 25, 891-902.	0.9	23
97	Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica, 2009, 39, 90-98.	0.5	23
98	Antiretroviral and Statin Drug-Drug Interactions. Cardiology in Review, 2009, 17, 44-47.	0.6	33
99	Agents and mechanisms of toxic myopathy. Current Opinion in Neurology, 2009, 22, 506-515.	1.8	46
100	Evidence-Based Guidelines for Cardiovascular Risk Reduction. Journal of Cardiovascular Nursing, 2009, 24, 429-438.	0.6	7
102	Drug-Drug Interactions Between Raltegravir and Pravastatin in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 82-86.	0.9	11
103	Pitavastatin: a distinctive lipid-lowering drug. Clinical Lipidology, 2010, 5, 309-323.	0.4	14
104	Pharmacogenetics of Drug Transporters. Current Pharmaceutical Design, 2010, 16, 220-230.	0.9	93
105	Statin myopathy: a review of recent progress. Current Opinion in Rheumatology, 2010, 22, 644-650.	2.0	69
106	Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?. Pharmacogenomics, 2010, 11, 959-971.	0.6	9
107	Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. European Journal of Clinical Pharmacology, 2010, 66, 285-290.	0.8	30
108	Perspectives of the non-statin hypolipidemic agents. , 2010, 127, 19-40.		80
109	Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer, 2010, 10, 103.	1.1	135
110	Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiology and Drug Safety, 2010, 19, 75-81.	0.9	46
111	Muscle toxicity with statins. Pharmacoepidemiology and Drug Safety, 2010, 19, 223-231.	0.9	34
112	Fruit juice inhibition of uptake transport: a new type of foodâ€“drug interaction. British Journal of Clinical Pharmacology, 2010, 70, 645-655.	1.1	195
113	Lack of clinically relevant drugâ€“drug interactions when dalcetrapib is coâ€administered with ezetimibe. British Journal of Clinical Pharmacology, 2010, 70, 825-833.	1.1	12
114	Drugâ€“drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. Journal of Internal Medicine, 2010, 268, 530-539.	2.7	61

#	Article	IF	Citations
115	Effects of ciclosporin therapy on xylazineÃ¢Â€ÂŠ/Ã¢Â€ÂŠketamine anaesthesia in a rat model. Journal of Veterinary Pharmacology and Therapeutics, 2010, 33, 100-102.	0.6	3
116	UDP-Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo. Clinical Pharmacology and Therapeutics, 2010, 87, 65-73.	2.3	98
117	Transporter Pharmacogenetics and Statin Toxicity. Clinical Pharmacology and Therapeutics, 2010, 87, 130-133.	2.3	299
118	Pharmacokinetic and Pharmacodynamic Interactions Between the Immunosuppressant Sirolimus and the Lipid-Lowering Drug Ezetimibe in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2010, 87, 663-667.	2.3	22
119	Grapefruit Juice Greatly Reduces the Plasma Concentrations of the OATP2B1 and CYP3A4 Substrate Aliskiren. Clinical Pharmacology and Therapeutics, 2010, 88, 339-342.	2.3	91
120	Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast. Clinical Pharmacology and Therapeutics, 2010, 88, 223-230.	2.3	54
121	Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236.	21.5	2,886
122	Clinically relevant drug interactions of current antifungal agents. Mycoses, 2010, 53, 95-113.	1.8	67
123	Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evidence, 2010, 5, 91.	4.7	19
124	Pharmacologic Interactions in the CICU. , 2010, , 516-531.		1
125	Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia. Vascular Health and Risk Management, 2010, 6, 997.	1.0	6
126	Inhibition of Hepatic Organic Anion-Transporting Polypeptide by RNA Interference in Sandwich-Cultured Human Hepatocytes: An In Vitro Model to Assess Transporter-Mediated Drug-Drug Interactions. Drug Metabolism and Disposition, 2010, 38, 1612-1622.	1.7	21
127	Association of the TNF-Â-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects. Diabetes Care, 2010, 33, 463-466.	4.3	10
128	Basic Science Review Section: Statin Therapyâ€"Part II: Clinical Considerations for Cardiovascular Disease. Vascular and Endovascular Surgery, 2010, 44, 421-433.	0.3	19
129	Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. Current Gerontology and Geriatrics Research, 2010, 2010, 1-9.	1.6	10
130	Effects of Concomitant Therapy with Diltiazem on the Lipid Responses to Simvastatin in Chinese Subjects. Journal of Clinical Pharmacology, 2010, 50, 1151-1158.	1.0	8
131	Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia. Expert Review of Cardiovascular Therapy, 2010, 8, 1079-1090.	0.6	14
132	Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins. Circulation Research, 2010, 106, 297-306.	2.0	171

#	Article	IF	Citations
133	Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes. Drug Metabolism and Disposition, 2010, 38, 1589-1597.	1.7	81
134	Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drugâ€“drug interaction to support regulatory submissions. Xenobiotica, 2010, 40, 24-37.	0.5	28
135	Ongoing Challenges in Drug Interaction Safety: from Exposure to Pharmacogenomics. Drug Metabolism and Pharmacokinetics, 2010, 25, 62-71.	1.1	12
136	Management of Dyslipidemia in Cushingâ€™s Syndrome. Neuroendocrinology, 2010, 92, 91-95.	1.2	23
137	Managing comorbid disease in patients with psoriasis. BMJ: British Medical Journal, 2010, 340, b5666-b5666.	2.4	114
138	The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics Journal, 2010, 10, 1-11.	0.9	141
139	Efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 621-632.	1.5	60
140	Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drugâ€Drug Interactions. Journal of Clinical Pharmacology, 2010, 50, 1188-1201.	1.0	20
142	Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metabolism Reviews, 2010, 42, 380-401.	1.5	93
143	Impact of Recipient Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1463-1466.	2.0	40
144	Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes. Toxicology in Vitro, 2010, 24, 1610-1618.	1.1	34
146	Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk. American Journal of Medicine, 2010, 123, 151-157.	0.6	65
147	Pitavastatin â€“ pharmacological profile from early phase studies. Atherosclerosis Supplements, 2010, 11, 3-7.	1.2	37
149	No clinically relevant drugâ€“drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opinion on Investigational Drugs, 2010, 19, 1135-1145.	1.9	16
150	Atorvastatin: safety and tolerability. Expert Opinion on Drug Safety, 2010, 9, 667-674.	1.0	38
151	Lipid Lowering for Secondary Prevention of Cardiovascular Disease in Older Adults. Drugs and Aging, 2010, 27, 959-972.	1.3	13
152	In Vitro Techniques to Study Transporter-Based DDI. , 2010, , 237-255.		1
153	Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews, 2011, 63, 157-181.	7.1	546

#	Article	IF	Citations
154	Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin. Journal of Clinical Pharmacology, 2011, 51, 378-388.	1.0	43
155	pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1. Molecular Pharmaceutics, 2011, 8, 1303-1313.	2.3	97
156	Cree antidiabetic plant extracts display mechanism-based inactivation of CYP3A4. Canadian Journal of Physiology and Pharmacology, 2011, 89, 13-23.	0.7	15
157	Impact ofSLCO1B1(OATP1B1) andABCG2(BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica, 2011, 41, 639-651.	0.5	53
158	Triazole antifungal agents drugâ€“drug interactions involving hepatic cytochrome P450. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1411-1429.	1.5	42
159	Emerging Toxic Neuropathies and Myopathies. Neurologic Clinics, 2011, 29, 679-687.	0.8	13
160	Pharmacogenetics of drug transporters in the enterohepatic circulation. Pharmacogenomics, 2011, 12, 611-631.	0.6	33
161	Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs. Clinical Pharmacokinetics, 2011, 50, 25-39.	1.6	70
162	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology, 2011, 27, 635-662.	0.8	160
163	Profiling of a Prescription Drug Library for Potential Renal Drugâ€“Drug Interactions Mediated by the Organic Cation Transporter 2. Journal of Medicinal Chemistry, 2011, 54, 4548-4558.	2.9	141
164	Inferring statin-induced gene regulatory relationships in primary human hepatocytes. Bioinformatics, 2011, 27, 2473-2477.	1.8	19
165	Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren. Journal of Clinical Pharmacology, 2011, 51, 359-367.	1.0	54
166	Pitavastatin: An overview. Atherosclerosis Supplements, 2011, 12, 271-276.	1.2	48
167	Drug safety evaluation of rosuvastatin. Expert Opinion on Drug Safety, 2011, 10, 969-986.	1.0	27
168	The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis, 2011, 215, 23-29.	0.4	97
169	Frequency of Common Variants in Genes Involved in Lipid-Lowering Response to Statins in Chilean Subjects with Hypercholesterolemia. International Journal of Morphology, 2011, 29, 1296-1302.	0.1	1
170	Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease. Yonsei Medical Journal, 2011, 52, 734.	0.9	20
171	HIV and HAART-Associated Dyslipidemia. Open Cardiovascular Medicine Journal, 2011, 5, 49-63.	0.6	125

#	Article	IF	Citations
172	The influence of high-dose simvastatin and diltiazem on myocardium in rabbits: a haemodynamic study. Archives of Medical Science, 2011, 3, 388-396.	0.4	0
173	Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. Frontiers in Pharmacology, 2011, 2, 41.	1.6	41
174	Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clinical Pharmacology: Advances and Applications, 2011, 3, 13.	0.8	22
175	The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action. Pharmacogenetics and Genomics, 2011, 21, 741-750.	0.7	28
176	The Effect of the Newly Developed Angiotensin Receptor II Antagonist Fimasartan on the Pharmacokinetics of Atorvastatin in Relation to OATP1B1 in Healthy Male Volunteers. Journal of Cardiovascular Pharmacology, 2011, 58, 492-499.	0.8	29
178	Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 419-425.	0.7	16
179	Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. British Journal of Clinical Pharmacology, 2011, 72, 321-329.	1.1	63
180	Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. British Journal of Clinical Pharmacology, 2011, 72, 434-441.	1.1	34
181	A SHARP Study, But With Blunted Conclusions. Seminars in Dialysis, 2011, 24, 684-685.	0.7	1
182	Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia, 2011, 52, 1351-1358.	2.6	27
183	Effect of Atorvastatin on CYP2C9 Metabolic Activity as Measured by the Formation Rate of Losartan Metabolite in Hypercholesterolaemic Patients. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 73-77.	1.2	11
184	A Population Pharmacokineticâ€“Pharmacodynamic Model for Simvastatin that Predicts Lowâ€Density Lipoproteinâ€Cholesterol Reduction in Patients with Primary Hyperlipidaemia. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 156-163.	1.2	35
185	Drug Interactions Between the Immunosuppressant Tacrolimus and the Cholesterol Absorption Inhibitor Ezetimibe in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2011, 89, 524-528.	2.3	13
186	The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions. , 2011, , 285-313.		2
187	Drugâ€“drug interactions with statins: will pitavastatin overcome the statinsâ€™ Achillesâ€™ heel?. Current Medical Research and Opinion, 2011, 27, 1551-1562.	0.9	55
188	Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. Chemical Research in Toxicology, 2011, 24, 1345-1410.	1.7	569
189	Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. European Journal of Clinical Pharmacology, 2011, 67, 633-641.	0.8	36
190	Effect of ABCB1 Genotype on Pre- and Post-Cardiac Transplantation Plasma Lipid Concentrations. Journal of Cardiovascular Translational Research, 2011, 4, 304-312.	1.1	16

#	Article	IF	Citations
191	Role of transporters in drug interactions. Archives of Pharmacal Research, 2011, 34, 1865-1877.	2.7	158
192	Use of cyclodextrins as solubilizing agents for simvastatin: Effect of hydroxypropyl-Î²-cyclodextrin on lactone/hydroxyacid aqueous equilibrium. International Journal of Pharmaceutics, 2011, 404, 49-56.	2.6	25
193	The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica, 2011, 41, 519-529.	0.5	54
194	The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 664-678.	2.2	25
195	Xenosensors CAR and PXR at Work: Impact on Statin Metabolism. Current Drug Metabolism, 2011, 12, 300-311.	0.7	10
196	Which Sources of Flavonoids: Complex Diets or Dietary Supplements?. Advances in Nutrition, 2011, 2, 8-14.	2.9	172
197	Cytochrome P450-mediated cardiovascular drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1065-1082.	1.5	26
198	Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients. Indian Journal of Pharmacology, 2011, 43, 385.	0.4	8
199	Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs. Drug Metabolism and Disposition, 2011, 39, 1196-1202.	1.7	91
200	Myoclonus associated with long-term use of diltiazem. American Journal of Health-System Pharmacy, 2011, 68, 1707-1710.	0.5	6
201	Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. Croatian Medical Journal, 2011, 52, 604-614.	0.2	34
202	Pitavastatin: finding its place in therapy. Therapeutic Advances in Chronic Disease, 2011, 2, 101-117.	1.1	13
203	The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica, 2012, 42, 28-45.	0.5	51
204	Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	0.5	30
205	Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. European Heart Journal, 2012, 33, 2151-2162.	1.0	37
206	Effects ofGinkgo bilobaextracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica, 2012, 42, 784-790.	0.5	21
207	The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1531-1548.	1.5	15
208	Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Annals of Oncology, 2012, 23, 2470-2471.	0.6	33

#	Article	IF	Citations
209	Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model. Xenobiotica, 2012, 42, 327-338.	0.5	16
210	Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro. Drug Metabolism and Disposition, 2012, 40, 655-661.	1.7	75
211	Effect of Lycopene and Tomato Products on Cholesterol Metabolism. Annals of Nutrition and Metabolism, 2012, 61, 126-134.	1.0	125
212	Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia. Clinical Medicine Insights: Endocrinology and Diabetes, 2012, 5, CMED.S7591.	1.0	15
213	Cardiovascular Complications in Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation. Seminars in Hematology, 2012, 49, 25-34.	1.8	32
214	Potential drug interactions associated with treatments for Type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Review of Clinical Pharmacology, 2012, 5, 31-42.	1.3	17
216	Mechanisms and Genetics of Drug Transport. , 2012, , 217-237.		0
217	Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions. Pharmaceutical Research, 2012, 29, 2860-2873.	1.7	122
218	Inhibition of Cholesterol Absorption: Targeting the Intestine. Pharmaceutical Research, 2012, 29, 3235-3250.	1.7	15
219	Pediatric Pharmacogenomics. Pediatric Clinics of North America, 2012, 59, 1017-1037.	0.9	11
220	Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 745-758.	1.5	10
221	Safety of statins: an update. Therapeutic Advances in Drug Safety, 2012, 3, 133-144.	1.0	82
222	Increased toxicity when fibrates and statins are administered in combination â€“ A metabolomics approach with rats. Toxicology Letters, 2012, 211, 187-200.	0.4	24
223	Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clinica Chimica Acta, 2012, 413, 495-501.	0.5	42
224	Statin induced myotoxicity. European Journal of Internal Medicine, 2012, 23, 317-324.	1.0	120
225	Prediction of the in vivo OATP1B1-mediated drugâ€“drug interaction potential of an investigational drug against a range of statins. European Journal of Pharmaceutical Sciences, 2012, 47, 244-255.	1.9	46
226	Inhibition of Interferon-beta Responses in Multiple Sclerosis Immune Cells Associated With High-Dose Statins. Archives of Neurology, 2012, 69, 1303.	4.9	47
227	Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin. Clinical Pharmacokinetics, 2012, 51, 147-162.	1.6	90

#	Article	IF	Citations
229	Simvastatin interactions with other drugs. Expert Opinion on Drug Safety, 2012, 11, 439-444.	1.0	29
230	Understanding the Critical Disposition Pathways of Statins to Assess Drugâ€“Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1. Clinical Pharmacology and Therapeutics, 2012, 92, 584-598.	2.3	175
231	Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics, 2012, 13, 223-231.	0.6	44
232	Statin drug interactions and related adverse reactions. Expert Opinion on Drug Safety, 2012, 11, 933-946.	1.0	87
233	Pharmacogenomic Mechanisms of Drug Toxicity. , 2012, , 285-306.		0
234	Statin-Induced Muscle Toxicity. , 2012, , 945-954.		0
235	Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. Journal of Personalized Medicine, 2012, 2, 158-174.	1.1	14
236	The contraindication of comedication drugs and drug utilization review. Journal of the Korean Medical Association, 2012, 55, 484.	0.1	4
237	Management of severe hypertriglyceridemia in the hospital: A review. Journal of Hospital Medicine, 2012, 7, 431-438.	0.7	17
238	Coâ€administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiology and Drug Safety, 2012, 21, 485-493.	0.9	30
239	Persistent Use of Againstâ€Łabel Statinâ€Fibrate Combinations from 2003â€“2009 Despite United States Food and Drug Administration Dose Restrictions. Pharmacotherapy, 2012, 32, 623-630.	1.2	9
240	A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 79-85.	2.2	165
241	Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics, 2012, 13, 579-594.	0.6	57
242	Effects of atorvastatin metabolites on induction of drugâ€metabolizing enzymes and membrane transporters through human pregnane X receptor. British Journal of Pharmacology, 2012, 165, 1595-1608.	2.7	47
243	OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. British Journal of Pharmacology, 2012, 165, 1260-1287.	2.7	627
244	Towards Safer and More Predictable Drug Treatment â€“ Reflections from Studies of the First <scp>BCPT</scp> Prize Awardee. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 207-218.	1.2	9
246	Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. European Journal of Pharmacology, 2012, 674, 95-103.	1.7	47
247	Inhibition of hepatic uptake transporters by flavonoids. European Journal of Pharmaceutical Sciences, 2012, 46, 79-85.	1.9	59

#	Article	IF	Citations
248	Dyslipidemia and Its Therapeutic Challenges in Renal Transplantation. American Journal of Transplantation, 2012, 12, 1975-1982.	2.6	67
249	Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicology and Applied Pharmacology, 2012, 259, 263-268.	1.3	78
250	In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drugâ€“Drug Interactions. Pharmaceutical Research, 2012, 29, 411-426.	1.7	108
251	Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin. European Journal of Clinical Pharmacology, 2013, 69, 1235-1245.	0.8	10
252	Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. European Journal of Clinical Pharmacology, 2013, 69, 523-532.	0.8	24
253	Intolerance to Statins: Mechanisms and Management. Diabetes Care, 2013, 36, S325-S330.	4.3	133
255	Statin Toxicity From Macrolide Antibiotic Coprescription. Annals of Internal Medicine, 2013, 158, 869.	2.0	132
256	Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans of the rat liver. Japanese Journal of Radiology, 2013, 31, 386-392.	1.0	5
257	Statins in Lymphangioleiomyomatosis. Simvastatin and Atorvastatin Induce Differential Effects on tuberous sclerosis complex 2â€“Null Cell Growth and Signaling. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 704-709.	1.4	29
258	Drugâ€“Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. Clinical Pharmacokinetics, 2013, 52, 815-831.	1.6	116
259	Connecting the Dots: Applications of Network Medicine in Pharmacology and Disease. Clinical Pharmacology and Therapeutics, 2013, 94, 659-669.	2.3	35
260	Searching the place of pitavastatin in the current treatment of patients with dyslipidemia. Expert Review of Cardiovascular Therapy, 2013, 11, 1597-1612.	0.6	4
261	Emerging Toxic Neuropathies and Myopathies. Psychiatric Clinics of North America, 2013, 36, 209-218.	0.7	9
262	Drugâ€“Vitamin D Interactions. Nutrition in Clinical Practice, 2013, 28, 194-208.	1.1	93
263	Pitavastatin in cardiometabolic disease: therapeutic profile. Cardiovascular Diabetology, 2013, 12, S2.	2.7	21
264	HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs, 2013, 13, 385-398.	1.0	4
265	Chronological Effects of Rifampicin Discontinuation on Cytochrome P450 Activity in Healthy Japanese Volunteers, Using the Cocktail Method. Clinical Pharmacology and Therapeutics, 2013, 94, 702-708.	2.3	31
266	CYP2C9andABCG2polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a caseâ€“control study. Pharmacogenomics, 2013, 14, 1419-1431.	0.6	29

#	Article	IF	Citations
267	Managing the Risks of Cardiac Therapy in Cancer Patients. Seminars in Oncology, 2013, 40, 210-217.	0.8	3
268	Lipid-lowing pharmacogenomics in Chinese patients. Expert Review of Cardiovascular Therapy, 2013, 11, 985-997.	0.6	3
269	Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1. Drug Metabolism and Disposition, 2013, 41, 592-601.	1.7	56
270	Grapefruitâ€“medication interactions: Forbidden fruit or avoidable consequences?. Cmaj, 2013, 185, 309-316.	0.9	183
271	Cardiovascular disease: Prevention and treatment in renal transplant recipients. Clinical Queries Nephrology, 2013, 2, 184-196.	0.2	0
272	Role of membrane transporters in drug interactions. Clinical Therapeutics, 2013, 35, e122.	1.1	1
273	Foodâ€“drug interactions: Effect of capsaicin on the pharmacokinetics of simvastatin and its active metabolite in rats. Food and Chemical Toxicology, 2013, 53, 168-173.	1.8	25
274	Clopidogrel and the possibility of drugâ€“drug interaction in primary health care. Journal of Young Pharmacists, 2013, 5, 18-21.	0.1	3
275	Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochemical and Biophysical Research Communications, 2013, 439, 221-227.	1.0	45
276	From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. International Journal of Pharmaceutics, 2013, 452, 14-35.	2.6	63
277	Association of Liver Stiffness with Hepatic Expression of Pharmacokinetically Important Genes in Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2013, 37, E17-22.	1.4	17
278	Informatics confronts drugâ€“drug interactions. Trends in Pharmacological Sciences, 2013, 34, 178-184.	4.0	153
279	High-dose supplementation with natural Î±-tocopherol does neither alter the pharmacodynamics of atorvastatin nor its phase I metabolism in guinea pigs. Toxicology and Applied Pharmacology, 2013, 266, 452-458.	1.3	11
280	Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. International Journal of Pharmaceutics, 2013, 444, 18-24.	2.6	64
281	The Development and Evaluation of Triage Algorithms for Early Discovery of Adverse Drug Interactions. Drug Safety, 2013, 36, 371-388.	1.4	27
282	Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics, 2013, 14, 981-995.	0.6	20
283	The Generation, Detection, and Effects of Reactive Drug Metabolites. Medicinal Research Reviews, 2013, 33, 985-1080.	5.0	73
284	Elucidation of the biochemical basis for a clinical drugâ€“drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778â€‰875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. Xenobiotica, 2013, 43, 963-972.	0.5	8

#	Article	IF	Citations
285	An Integrated in Vitro Model for Simultaneous Assessment of Drug Uptake, Metabolism, and Efflux. Molecular Pharmaceutics, 2013, 10, 3152-3163.	2.3	14
286	Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. Xenobiotica, 2013, 43, 920-931.	0.5	28
287	Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature review. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 246-248.	0.7	8
288	Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response. Drug Metabolism and Pharmacokinetics, 2013, 28, 4-18.	1.1	108
289	Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. BMJ Open, 2013, 3, e002857.	0.8	20
290	Subclinical Carotid Atherosclerosis: Short-term Natural History of Lipid-rich Necrotic Coreâ€"A Multicenter Study with MR Imaging. Radiology, 2013, 268, 61-68.	3.6	59
291	Cyclosporine A and lovastatin: the good and the bad, but who will be the winner?. American Journal of Physiology - Renal Physiology, 2013, 305, F643-F644.	1.3	0
292	Rhabdomyolysis after Concomitant Use of Simvastatin and Voriconazole in an Allogeneic Stem Cell Transplant Patient. Journal of Pharmacy Technology, 2013, 29, 135-138.	0.5	2
293	Organic anion-transporting polypeptides (OATPs/SLCOs). , 2013, , 353-454.		0
294	Lysosomal Sequestration (Trapping) of Lipophilic Amine (Cationic Amphiphilic) Drugs in Immortalized Human Hepatocytes (Fa2N-4 Cells). Drug Metabolism and Disposition, 2013, 41, 897-905.	1.7	196
295	Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabolism and Drug Interactions, 2013, 28, 49-58.	0.3	16
296	Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 635-644.	1.3	25
297	Drug interactions with statins. Acta Pharmaceutica, 2013, 63, 277-293.	0.9	35
298	Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. Clinical Pharmacology in Drug Development, 2013, 2, 195-200.	0.8	10
299	Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin andGinkgo bilobaextracts in healthy subjects. Xenobiotica, 2013, 43, 862-867.	0.5	21
300	Functional Alterations of Intestinal P-Glycoprotein under Diabetic Conditions. Biological and Pharmaceutical Bulletin, 2013, 36, 1381-1390.	0.6	27
301	National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool. Therapeutics and Clinical Risk Management, 2013, 9, 491.	0.9	16
302	Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy. Arquivos Brasileiros De Endocrinologia E Metabologia, 2013, 57, 513-519.	1.3	12

#	Article	IF	Citations
303	Adherence to Drug Label Recommendations for Avoiding Drug Interactions Causing Statin-Induced Myopathyâ€“A Nationwide Register Study. PLoS ONE, 2013, 8, e69545.	1.1	14
304	Pharmacogenetics in Cardiovascular Diseases. , 2013, , 133-182.		3
305	Muscular effects of statins in the elderly female: a review. Clinical Interventions in Aging, 2013, 8, 47.	1.3	63
306	A New Perspective on the Development of Cholesterol- Lowering Products. , 2013, , .		1
307	Membrane transporters and transporter substrates as biomarkers for drug pharmacokinetics, pharmacodynamics, and toxicity/adverse events. , 2014, , 947-963.		2
308	A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. , 2014, 2014, 5703-6.		6
309	Inhibition of Protein Geranylgeranylation Specifically Interferes with CD40-Dependent B Cell Activation, Resulting in a Reduced Capacity To Induce T Cell Immunity. Journal of Immunology, 2014, 193, 5294-5305.	0.4	29
310	Prediction of Organic Anion-Transporting Polypeptide 1B1- and 1B3-Mediated Hepatic Uptake of Statins Based on Transporter Protein Expression and Activity Data. Drug Metabolism and Disposition, 2014, 42, 1514-1521.	1.7	95
311	A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans. , 2014, 2014, 5711-4.		5
312	Pharmacokinetic modeling of simvastatin, nelfinavir and their interaction in humans. , 2014, 2014, 5715-8.		1
313	Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia. Pharmacotherapy, 2014, 34, 227-239.	1.2	27
314	Statins and the risk of liver injury: a populationâ€based caseâ€control study. Pharmacoepidemiology and Drug Safety, 2014, 23, 719-725.	0.9	17
315	Acute Rhabdomyolysis Associated with Coadministration of Levofloxacin and Simvastatin in a Patient with Normal Renal Function. Case Reports in Medicine, 2014, 2014, 1-4.	0.3	5
316	Toxic Myopathies. , 2014, , 1403-1426.		0
317	The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenetics and Genomics, 2014, 24, 43-51.	0.7	42
318	Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE study. Journal of Clinical Lipidology, 2014, 8, 69-76.	0.6	40
319	Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Translational Research, 2014, 164, 85-109.	2.2	46
320	A clinician's guide to statin drug-drug interactions. Journal of Clinical Lipidology, 2014, 8, S30-S46.	0.6	124

#	Article	IF	Citations
321	Statins and skeletal muscles toxicity: From clinical trials to everyday practice. Pharmacological Research, 2014, 88, 107-113.	3.1	48
322	Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein. Drug Metabolism and Disposition, 2014, 42, 182-192.	1.7	77
323	Protein Restoration in Low-Birth-Weight Rat Offspring Derived from Maternal Low-Protein Diet Leads to Elevated Hepatic CYP3A and CYP2C11 Activity in Adulthood. Drug Metabolism and Disposition, 2014, 42, 221-228.	1.7	14
324	Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?. European Journal of Clinical Pharmacology, 2014, 70, 775-789.	0.8	8
325	Addressing Statin Adverse Effects in the Clinic. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 533-542.	1.0	22
326	A hypothesis about the potential role of statin administration as adjuvant treatment in the management of Merlin-deficient tumors. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2014, 1, 11-15.	0.2	1
327	Pharmacogenomics, Lipid Disorders, and Treatment Options. Clinical Pharmacology and Therapeutics, 2014, 96, 36-47.	2.3	26
328	Iatrogenic neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 121, 1635-1671.	1.0	2
329	Mechanisms and assessment of statinâ€•related muscular adverse effects. British Journal of Clinical Pharmacology, 2014, 78, 454-466.	1.1	88
330	Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 51-65.	1.5	33
331	Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882. European Journal of Clinical Pharmacology, 2014, 70, 675-684.	0.8	3
332	Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 452-458.	1.3	39
333	Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Digestive and Liver Disease, 2014, 46, 720-725.	0.4	32
334	Arsonists and Firefighters. Circulation, 2014, 129, 2368-2370.	1.6	0
335	Troponin leakâ€”Janus face of polypharmacy. American Journal of Emergency Medicine, 2014, 32, 1129.	0.7	0
336	Lipid lowering in liver and chronic kidney disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 339-352.	2.2	9
338	Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy. Circulation Journal, 2014, 78, 679-684.	0.7	13
340	Using Positron Emission Tomography to Study Transporter-Mediated Drugâ€“Drug Interactions in Tissues. Clinical Pharmacology and Therapeutics, 2014, 96, 206-213.	2.3	31

#	Article	IF	Citations
341	HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients. Transplantation, 2014, 97, 419-425.	0.5	9
342	Frequencies of Single-Nucleotide Polymorphisms and Haplotypes of the SLCO1B1 Gene in Selected Populations of the Western Balkans. Balkan Journal of Medical Genetics, 2015, 18, 5-22.	0.5	6
344	The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology, 2015, 80, 473-479.	1.1	18
345	Statin intolerance. Current Opinion in Lipidology, 2015, 26, 492-501.	1.2	32
346	Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. PLoS ONE, 2015, 10, e0137720.	1.1	19
347	Pharmacokinetic Drugâ€“Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 44-51.	0.9	11
348	Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities. Frontiers in Medicine, 2015, 2, 1.	1.2	68
350	Managing drug interactions in HIV-infected adults with comorbid illness. Cmaj, 2015, 187, 36-43.	0.9	37
351	Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins. Drug Metabolism and Personalized Therapy, 2015, 30, 175-188.	0.3	27
352	Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole. , 2015, 2015, 3246-9.		3
353	Metrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling. Journal of Cheminformatics, 2015, 7, 31.	2.8	47
354	Genetic Polymorphisms and Function of the Organic Anion-Transporting Polypeptide 1A2 and Its Clinical Relevance in Drug Disposition. Pharmacology, 2015, 95, 201-208.	0.9	33
355	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Cmaj, 2015, 187, 174-180.	0.9	54
356	Transporter-mediated tissue targeting of therapeutic molecules in drug discovery. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 993-997.	1.0	14
357	Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. European Journal of Clinical Pharmacology, 2015, 71, 15-23.	0.8	4
358	Drugâ€“drug interactions that interfere with statin metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1435-1447.	1.5	63
359	Statins: Risk-Benefits and Role in Treating Dyslipidemias. Contemporary Endocrinology, 2015, , 403-421.	0.3	0
360	Effect of extractions from Ephedra sinica Stapf on hyperlipidemia in mice. Experimental and Therapeutic Medicine, 2015, 9, 619-625.	0.8	20

#	Article	IF	Citations
361	Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). Pharmaceutical Research, 2015, 32, 3785-3802.	1.7	231
362	Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drugâ€“Drug Interactions. Clinical Pharmacokinetics, 2015, 54, 1205-1222.	1.6	42
363	Physiologically based pharmacokinetic modeling of disposition and drugâ€“drug interactions for atorvastatin and its metabolites. European Journal of Pharmaceutical Sciences, 2015, 77, 216-229.	1.9	31
364	Statin Intolerance: Diagnosis and Remedies. Current Cardiology Reports, 2015, 17, 27.	1.3	32
365	Risk identification and possible countermeasures for muscle adverse effects during statin therapy. European Journal of Internal Medicine, 2015, 26, 82-88.	1.0	67
366	Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 809-820.	2.0	24
367	Ethnic Variability in the Expression of Hepatic Drug Transporters: Absolute Quantification by an Optimized Targeted Quantitative Proteomic Approach. Drug Metabolism and Disposition, 2015, 43, 1045-1055.	1.7	48
368	Metabolic disorders associated with the use of targeted cancer therapies. Current Opinion in Oncology, 2015, 27, 258-266.	1.1	3
369	Comorbidities in Cushingâ€™s disease. Pituitary, 2015, 18, 188-194.	1.6	73
370	Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman. European Journal of Contraception and Reproductive Health Care, 2015, 20, 231-235.	0.6	0
371	Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. Drug Metabolism and Disposition, 2015, 43, 1655-1660.	1.7	25
372	Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-Î²-Glucuronide. Molecular Pharmaceutics, 2015, 12, 3943-3952.	2.3	33
373	Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and) Tj ETQq0 0 0 rgBT /Overlock 4395-4404.	2.3	36
374	Computational classification models for predicting the interaction of compounds with hepatic organic ion importers. Drug Metabolism and Pharmacokinetics, 2015, 30, 347-351.	1.1	9
375	Comparative proteomic analysis using 2DEâ€LCâ€MS/MS reveals the mechanism of Fuzhuan brick tea extract against hepatic fat accumulation in rats with nonalcoholic fatty liver disease. Electrophoresis, 2015, 36, 2002-2016.	1.3	25
376	Organic Anion Transporting Polypeptideâ€Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease. Clinical Pharmacology and Therapeutics, 2015, 97, 159-166.	2.3	41
377	Prevalence of Potential and Clinically Relevant Statinâ€“Drug Interactions in Frail and Robust Older Inpatients. Drugs and Aging, 2015, 32, 849-856.	1.3	25
378	ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a caseâ€“control study. Pharmacogenomics, 2015, 16, 803-815.	0.6	32

#	Article	IF	Citations
379	Metabolic comorbidities in Cushing's syndrome. European Journal of Endocrinology, 2015, 173, M133-M157.	1.9	128
380	Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin. Human and Experimental Toxicology, 2015, 34, 828-837.	1.1	18
382	Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 87-94.	0.6	7
383	Muscle- and skeletal-related side-effects of statins: tip of the iceberg?. European Journal of Preventive Cardiology, 2016, 23, 88-110.	0.8	58
384	Ubiquinone, Ezetimibe/Simvastatin and Rosuvastatin Effects on Mitochondrial Function in Diabetic Polyneuropathy. , 0, , .		0
385	Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice. International Journal of Nanomedicine, 2016, 11, 885.	3.3	21
387	Statin-associated rhabdomyolysis triggered by drugâ€“drug interaction with itraconazole. BMJ Case Reports, 2016, 2016, bcr2016216457.	0.2	15
388	Molecular mechanisms of statin intolerance. Archives of Medical Science, 2016, 3, 645-658.	0.4	58
389	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. International Journal of Molecular Sciences, 2016, 17, 217.	1.8	73
390	Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study. PLoS ONE, 2016, 11, e0157531.	1.1	8
391	Effect of Omeprazole on the Pharmacokinetics of Rosuvastatin in Healthy Male Volunteers. American Journal of Therapeutics, 2016, 23, e1514-e1523.	0.5	6
392	Neuromuscular Effects of Rocuronium Bromide in Patients in Statin Therapy for at least Three Months. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 582-587.	1.2	3
393	Statin myopathy. Current Opinion in Cardiology, 2016, 31, 417-425.	0.8	7
394	In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 424-431.	0.7	21
395	Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. Clinical Pharmacology and Therapeutics, 2016, 100, 259-267.	2.3	59
396	Hepatic Clearance Prediction of Nine Human Immunodeficiency Virus Protease Inhibitors in Rat. Journal of Pharmaceutical Sciences, 2016, 105, 846-853.	1.6	5
397	Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Pharmacogenomics, 2016, 17, 615-631.	0.6	4
398	Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacological Research, 2016, 107, 1-18.	3.1	57

#	Article	IF	Citations
399	Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 382-393.	1.3	88
400	Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. European Journal of Clinical Pharmacology, 2016, 72, 859-867.	0.8	27
401	Biochemistry of Statins. Advances in Clinical Chemistry, 2016, 73, 127-168.	1.8	38
402	Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers. Medicine (United States), 2016, 95, e2487.	0.4	34
403	Statin-related myotoxicity. EndocrinologÃa Y NutriciÃ³n (English Edition), 2016, 63, 239-249.	0.5	4
404	Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. Chemical Research in Toxicology, 2016, 29, 1778-1788.	1.7	10
405	Data Mining of the US FDAâ€™s Adverse Events Reporting System Database to Evaluate Drugâ€“Drug Interactions Associated with Statin-Induced Rhabdomyolysis. Pharmaceutical Medicine, 2016, 30, 327-337.	1.0	4
408	Risk assessment and management of post-transplant diabetes mellitus. Metabolism: Clinical and Experimental, 2016, 65, 1559-1569.	1.5	15
409	Analysis and comparison of statin prescription patterns and outcomes according to clinical department. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 70-77.	0.7	16
410	Ranolazine in Cardiac Arrhythmia. Clinical Cardiology, 2016, 39, 170-178.	0.7	18
412	Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics, Proteomics and Bioinformatics, 2016, 14, 298-313.	3.0	227
413	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 2016, 134, e468-e495.	1.6	203
414	AB0184â€…Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 960.1-960.	0.5	0
415	ToxEvaluator: an integrated computational platform to aid the interpretation of toxicology study-related findings. Database: the Journal of Biological Databases and Curation, 2016, 2016, .	1.4	7
416	Hypocholesterolemic effects of diets containing different levels of kishk as a dried fermented milkâ€“whole wheat mixture in experimental rats. Journal of Ethnic Foods, 2016, 3, 117-123.	0.8	8
417	Skeletal muscle ultrastructure and function in statin-tolerant individuals. Muscle and Nerve, 2016, 53, 242-251.	1.0	17
418	Prevalence of statin-drug interactions in older people: a systematic review. European Journal of Clinical Pharmacology, 2016, 72, 513-521.	0.8	27
419	Overcoming Challenges With Statin Therapy. Journal of the American Heart Association, 2016, 5, .	1.6	49

#	Article	IF	Citations
420	Cardiovascular Pharmacogenomicsâ€"Implications for Patients With CKD. Advances in Chronic Kidney Disease, 2016, 23, 82-90.	0.6	12
421	Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake. Antimicrobial Agents and Chemotherapy, 2016, 60, 3096-3105.	1.4	21
422	Statin-related myotoxicity. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 239-249.	0.8	13
423	The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. Drug Metabolism and Disposition, 2016, 44, 692-699.	1.7	20
424	Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury. Journal of Pharmaceutical Sciences, 2016, 105, 443-459.	1.6	62
425	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews, 2016, 68, 168-241.	7.1	175
426	Statin tolerability: In defence of placebo-controlled trials. European Journal of Preventive Cardiology, 2016, 23, 891-896.	0.8	32
427	Analysis and prediction of drugâ€"drug interaction by minimum redundancy maximum relevance and incremental feature selection. Journal of Biomolecular Structure and Dynamics, 2017, 35, 312-329.	2.0	81
428	Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects. Clinical Pharmacology in Drug Development, 2017, 6, 66-75.	0.8	38
429	Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction. Saudi Pharmaceutical Journal, 2017, 25, 823-829.	1.2	6
432	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews, 2017, 55, 71-82.	3.4	56
433	Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome. Drug Metabolism and Disposition, 2017, 45, 501-511.	1.7	14
434	Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics, 2017, 56, 1461-1478.	1.6	41
435	Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia. , 2017, , 175-214.		0
437	Lifeâ€threatening drug interactions: what the physician needs to know. Internal Medicine Journal, 2017, 47, 501-512.	0.5	36
438	Recommendations for Managing Drugâ€"Drug Interactions with Statins and HIV Medications. American Journal of Cardiovascular Drugs, 2017, 17, 375-389.	1.0	36
439	Impact of the Herbal Breviscapine on the Pharmacokinetics of Simvastatin in Rats: The Involvement of CYP3A4. Drug Research, 2017, 67, 271-274.	0.7	8
440	Herbâ€"Drug Interactions of Commonly Used Chinese Medicinal Herbs. International Review of Neurobiology, 2017, 135, 197-232.	0.9	47

#	Article	IF	Citations
441	Evaluation of transporters in drug development: Current status and contemporary issues. Advanced Drug Delivery Reviews, 2017, 116, 100-118.	6.6	62
442	Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database. Drug Safety, 2017, 40, 895-909.	1.4	13
443	Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. International Journal of Cardiology, 2017, 228, 761-770.	0.8	21
444	Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 689-705.	0.6	55
445	Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Current Medical Research and Opinion, 2017, 33, 239-251.	0.9	18
446	Managing drugâ€“drug interactions with new directâ€acting antiviral agents in chronic hepatitis C. British Journal of Clinical Pharmacology, 2017, 83, 269-293.	1.1	62
447	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 83-95.	1.5	30
448	Diseaseâ€“Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. Clinical Pharmacokinetics, 2017, 56, 607-615.	1.6	62
449	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 2017, 38, 3569-3575.	1.0	41
450	Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy. Scientific Reports, 2017, 7, 18037.	1.6	4
451	Drug Classification and Drug Disposition Prediction. , 2017, , 102-129.		0
452	Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. International Journal of Molecular Sciences, 2017, 18, 104.	1.8	31
453	Statins do not Increase the Rate of Bleeding Among Warfarin Users. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 195-201.	1.2	6
454	Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 Gene. Drug Metabolism and Disposition, 2018, 46, 628-635.	1.7	17
455	Statin-related myopathies. Practical Neurology, 2018, 18, 97-105.	0.5	31
456	Response of PXR signaling pathway to simvastatin exposure in mosquitofish (Gambusia affinis) and its histological changes. Ecotoxicology and Environmental Safety, 2018, 154, 228-236.	2.9	14
457	Predictors of a successful statin reattempt after an adverse reaction. Journal of Clinical Lipidology, 2018, 12, 643-651.	0.6	7
458	The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy. Journal of Thrombosis and Thrombolysis, 2018, 46, 264-270.	1.0	3

#	Article	IF	Citations
459	The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection. Drug Metabolism and Disposition, 2018, 46, 1212-1225.	1.7	56
460	Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. Internal Medicine Journal, 2018, 48, 5-13.	0.5	21
461	Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. , 2018, , 119-172.		0
462	Oat Î²-glucan inhibits adipogenesis and hepatic steatosis in high fat diet-induced hyperlipidemic mice via AMPK signaling. Journal of Functional Foods, 2018, 41, 72-82.	1.6	25
463	Update on colchicine, 2017. Rheumatology, 2018, 57, i4-i11.	0.9	173
464	Utilization of Biologic and Systemic Agents in the Elderly. , 2018, , 281-294.		0
466	Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxford Medical Case Reports, 2018, 2018, omx104.	0.2	32
467	Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review. Critical Reviews in Analytical Chemistry, 2018, 48, 317-329.	1.8	14
469	Organic Anionâ€“Transporting Polypeptide (OATP)â€“Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. Drug Metabolism and Disposition, 2018, 46, 11-19.	1.7	30
470	Statin drug interactions and related adverse reactions: an update. Expert Opinion on Drug Safety, 2018, 17, 25-37.	1.0	114
471	Psoriasis and the metabolic syndrome. Clinics in Dermatology, 2018, 36, 21-28.	0.8	211
472	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8â€Mediated Metabolism of Montelukast in Humans. Clinical Pharmacology and Therapeutics, 2018, 104, 495-504.	2.3	14
473	Effect of multipleâ€dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. British Journal of Clinical Pharmacology, 2018, 84, 2877-2888.	1.1	20
474	Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics, 2018, 28, 153-164.	0.7	6
475	SLCO1B1 c.521T>C Genotyping in the Austrian Population Using 2 Commercial Real-Time Polymerase Chain Reaction Assays: An Implementation Study. Pharmacology, 2018, 102, 88-90.	0.9	2
476	Antifungal Agents. , 2018, , 425-501.		0
477	Concomitant use of statins and macrolide antibiotics and risk of serious renal events: A nationwide cohort study. International Journal of Cardiology, 2018, 269, 310-316.	0.8	1
478	Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers. Drug Design, Development and Therapy, 2018, Volume 12, 2301-2309.	2.0	5

#	Article	IF	Citations
479	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121733.	1.2	10
480	Identification of key transporters mediating uptake of aconitum alkaloids into the liver and kidneys and the potential mechanism of detoxification by active ingredients of liquorice. RSC Advances, 2019, 9, 16136-16146.	1.7	3
481	A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease. British Journal of Clinical Pharmacology, 2019, 85, 2878-2885.	1.1	8
482	Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. Biomedicine and Pharmacotherapy, 2019, 119, 109416.	2.5	25
483	Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 787-802.	1.5	6
484	Influence of Concomitant Treatments under Anticoagulants and Statins in Detecting Signals of Adverse Drug Reactions. Seminars in Thrombosis and Hemostasis, 2019, 45, 837-845.	1.5	5
485	A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2019, 41, 19-28.	1.0	16
486	Analysis of a Skeletal Muscle Injury and Drug Interactions in Lovastatin- and Fenofibrate-Coadministered Dogs. International Journal of Toxicology, 2019, 38, 192-201.	0.6	3
487	A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters. Drug Metabolism and Disposition, 2019, 47, 768-778.	1.7	43
488	Current Advances in Studying Clinically Relevant Transporters of the Solute Carrier (SLC) Family by Connecting Computational Modeling and Data Science. Computational and Structural Biotechnology Journal, 2019, 17, 390-405.	1.9	24
489	Enantiospecific Pharmacogenomics of Fluvastatin. Clinical Pharmacology and Therapeutics, 2019, 106, 668-680.	2.3	26
490	Pharmacokinetic Drugâ€Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. Journal of Clinical Pharmacology, 2019, 59, 1331-1339.	1.0	47
491	Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist, 2019, 24, 1103-1110.	1.9	101
492	Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study. Clinical Therapeutics, 2019, 41, 728-741.	1.1	4
493	Perpetrator effects of ciclosporin (Pâ€glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. British Journal of Clinical Pharmacology, 2019, 85, 1528-1537.	1.1	21
494	Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI. Case Reports in Medicine, 2019, 2019, 1-3.	0.3	5
495	Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca2+-dependent PKC activation. Journal of Molecular and Cellular Cardiology, 2019, 129, 314-325.	0.9	12
496	The transcription factor E4bp4 regulates the expression and activity of Cyp3a11 in mice. Biochemical Pharmacology, 2019, 163, 215-224.	2.0	14

#	Article	IF	Citations
497	Contemporary Drugâ€“Drug Interactions in HIV Treatment. Clinical Pharmacology and Therapeutics, 2019, 105, 1362-1377.	2.3	16
498	POTENTIAL DRUG-DRUG INTERACTIONS IN HEART FAILURE PATIENTS. International Journal of Pharmacy and Pharmaceutical Sciences, 2019, , 37-41.	0.3	2
499	Preparation and Evaluation of Atorvastatin-Loaded Nanoemulgel on Wound-Healing Efficacy. Pharmaceutics, 2019, 11, 609.	2.0	67
500	Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization. Scientific Reports, 2019, 9, 17747.	1.6	14
501	Association between venous thromboembolism events and fibrates: A comparative study. Therapie, 2019, 74, 421-430.	0.6	2
502	Effects of simvastatin on the PXR signaling pathway and the liver histology in Mugilogobius abei. Science of the Total Environment, 2019, 651, 399-409.	3.9	17
503	Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. Drug Metabolism and Disposition, 2019, 47, 377-385.	1.7	15
504	Pharmacologic Interactions. , 2019, , 432-445.e7.		0
505	Common Questions and Misconceptions in the Management of Renal Transplant Patients: A Guide for Health Care Providers in the Posttransplant Setting. Annals of Pharmacotherapy, 2019, 53, 419-429.	0.9	1
506	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e38-e81.	1.1	431
507	Safety and tolerability of highâ€intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus. Clinical Transplantation, 2019, 33, e13454.	0.8	10
508	Drugs and hepatic transporters: A review. Pharmacological Research, 2020, 154, 104234.	3.1	87
509	Clinically relevant drug interactions between statins and antidepressants. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 227-239.	0.7	24
510	Interaction potential between clarithromycin and individual statinsâ€”A systematic review. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 307-317.	1.2	14
511	Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. Journal of Clinical Medicine, 2020, 9, 22.	1.0	122
512	An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 809-822.	1.5	78
513	Pathophysiological mechanisms of statinâ€associated myopathies: possible role of the ubiquitinâ€proteasome system. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1177-1186.	2.9	14
514	Pharmacogenetics of Statin-Induced Myotoxicity. Frontiers in Genetics, 2020, 11, 575678.	1.1	33

#	Article	IF	Citations
515	<i>Coleus forskohlii</i> Extract Attenuated the Beneficial Effect of Diet-Treatment on NASH in Mouse Model. Journal of Nutritional Science and Vitaminology, 2020, 66, 191-199.	0.2	3
516	A userâ€™s guide to lorlatinib. Critical Reviews in Oncology/Hematology, 2020, 151, 102969.	2.0	26
517	Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners. Advances in Therapy, 2020, 37, 3019-3030.	1.3	27
518	Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. Clinical and Translational Science, 2020, 13, 1227-1235.	1.5	7
519	Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. Clinical and Translational Science, 2020, 13, 1236-1243.	1.5	20
520	Big data highlights the association between psoriasis and fibromyalgia: a population-based study. Immunologic Research, 2020, 68, 135-140.	1.3	9
521	Chia Seed Oil Prevents High Fat Diet Induced Hyperlipidemia and Oxidative Stress in Mice. European Journal of Lipid Science and Technology, 2020, 122, 1900443.	1.0	12
522	An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase. BMJ Case Reports, 2020, 13, e231839.	0.2	3
523	Association between rs4149056 variant in SLCO1B1 and early discontinuation of statin after acute myocardial infarction. Pharmacogenomics, 2020, 21, 163-172.	0.6	3
524	Predicting Drug-Drug Interactions Based on Integrated Similarity and Semi-Supervised Learning. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 168-179.	1.9	30
525	Evaluation of the inhibition of chlorophenols towards human cytochrome P450 3A4 and differences among various species. Science of the Total Environment, 2020, 724, 138187.	3.9	6
526	Real-life management of drugâ€“drug interactions between antiretrovirals and statins. Journal of Antimicrobial Chemotherapy, 2020, 75, 1972-1980.	1.3	8
527	Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. Drug Metabolism and Disposition, 2020, 48, 420-426.	1.7	26
528	Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 2020, 382, 1666-1668.	13.9	0
529	Atorvastatinâ€“Green Tea Interaction: Possible Mechanisms are Complicated, But Clinical Relevance is Not?. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 423-425.	0.6	0
530	Influence of Drugâ€“Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics, 2020, 59, 1037-1048.	1.6	5
531	DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus. Drug Safety, 2020, 43, 767-774.	1.4	4
532	Drugâ€drug interaction between warfarin and statins: A Danish cohort study. British Journal of Clinical Pharmacology, 2021, 87, 694-699.	1.1	15

#	Article	IF	Citations
533	Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. Japanese Journal of Clinical Oncology, 2021, 51, 37-44.	0.6	17
534	Cyclosporine. , 2021, , 187-198.e3.		4
535	Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models. Journal of Pharmaceutical Sciences, 2021, 110, 314-324.	1.6	11
536	Effect of Genetic Polymorphisms of Human SLC22A3 in the 5â€™-flanking Region on OCT3 Expression and Sebum Levels in Human Skin. Journal of Dermatological Science, 2021, 101, 4-13.	1.0	2
537	Osteogenic effects in a rat osteoporosis model and femur defect model by simvastatin microcrystals. Annals of the New York Academy of Sciences, 2021, 1487, 31-42.	1.8	7
538	Patientsâ€™ Use and Perceptions of a Drug-Drug Interaction Database: A Survey of Janusmed Interactions. Pharmacy (Basel, Switzerland), 2021, 9, 23.	0.6	5
539	Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions. Advances in Experimental Medicine and Biology, 2021, 1297, 27-42.	0.8	8
540	The role of vitamin D in statin treated patients complaining of myalagia. Cor Et Vasa, 2021, 63, 58-65.	0.1	0
543	Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlledÂtrials. Journal of Neurology, 2022, 269, 664-675.	1.8	14
544	Hepatic transporterâ€mediated pharmacokinetic drugâ€“drug interactions: Recent studies and regulatory recommendations. Biopharmaceutics and Drug Disposition, 2021, 42, 45-77.	1.1	3
545	Drug Interactions with Antihypertensives. Current Hypertension Reports, 2021, 23, 14.	1.5	8
546	Statin Therapy in Children. , 0, , .		0
547	Evaluation of the drugâ€“drug interaction potential for trazpiroben (TAK-906), a D₂/D₃ receptor antagonist for gastroparesis, towards cytochrome P450s and transporters. Xenobiotica, 2021, 51, 1-12.	0.5	7
548	Drug-drug interactions between vitamin K antagonists and statins: a systematic review. European Journal of Clinical Pharmacology, 2021, 77, 1435-1441.	0.8	2
549	Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. Pharmaceutics, 2021, 13, 709.	2.0	9
550	Evaluation of the Effects of Repeatâ€Dose Dabrafenib on the Singleâ€Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate). Clinical Pharmacology in Drug Development, 2021, 10, 1054-1063.	0.8	3
551	Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins. Drug Metabolism and Disposition, 2021, 49, 658-667.	1.7	19
552	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circulation Research, 2021, 128, 1973-1987.	2.0	10

#	Article	IF	Citations
553	Statin liver safety in nonâ€alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology, 2022, 88, 441-451.	1.1	28
554	Luminogenic Dâ€Luciferin Derivatives as OATP1B1 and 1B3 Substrates in Noâ€wash Assays â€. Photochemistry and Photobiology, 2021, , .	1.3	1
555	Comparative Hepatic and Intestinal Efflux Transport of Statins. Drug Metabolism and Disposition, 2021, 49, 750-759.	1.7	31
556	Statin and outcomes of coronavirus disease 2019 (COVID-19): AÂsystematic review, meta-analysis, and meta-regression. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1662-1670.	1.1	32
557	A Literature Review of the Potential Impact of Medication on Vitamin D Status. Risk Management and Healthcare Policy, 2021, Volume 14, 3357-3381.	1.2	19
558	Is It Time to Use Modeling of Cellular Transporter Homeostasis to Inform Drug-Drug Interaction Studies: Theoretical Considerations. AAPS Journal, 2021, 23, 102.	2.2	0
559	The Role of Lipid and the Benefit of Statin in Augmenting Rifampicin Effectivity for a Better Leprosy Treatment. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 246-259.	0.1	0
560	Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans. Clinical Pharmacology and Therapeutics, 2021, 110, 1622-1632.	2.3	20
561	Herb-drug interactions and toxicity: Underscoring potential mechanisms and forecasting clinically relevant interactions induced by common phytoconstituents via data mining and computational approaches. Food and Chemical Toxicology, 2021, 156, 112432.	1.8	10
562	OATPs: The SLCO Family of Organic Anion Transporting Polypeptide Transporters. RSC Drug Discovery Series, 2021, , 143-159.	0.2	0
564	Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drugâ€“drug interaction. Journal of Applied Toxicology, 2017, 37, 1438-1447.	1.4	20
565	ADME Pharmacogenetics and Its Impact on Drugâ€“Drug Interactions. , 2010, , 51-74.		3
566	Drugâ€“Drug Interactions: Designing Development Programs and Appropriate Product Labeling. , 2011, , 21-56.		11
567	The Role of Transporters in Drug Development: Regulatory Science Perspectives from the FDA. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 257-283.	0.2	2
568	Approach to Clinical and Genetic Characterization of Statin-Induced Myopathy. Methods in Molecular Biology, 2014, 1175, 67-90.	0.4	6
569	Analysis of Sinusoidal Drug Uptake Transporter Activities in Primary Human Hepatocytes. Methods in Molecular Biology, 2015, 1250, 287-302.	0.4	6
570	Optimization of Cyclophilin Inhibitors for Use in Antiviral Therapy. RSC Drug Discovery Series, 2013, , 384-418.	0.2	4
571	Cytochrome P450 drug interactions with statin therapy. Singapore Medical Journal, 2013, 54, 131-135.	0.3	19

#	Article	IF	Citations
572	Co-Medication of Statins with Contraindicated Drugs. PLoS ONE, 2015, 10, e0125180.	1.1	11
573	An updated review of interactions of statins with antibacterial and antifungal agents. Journal of Translational Science, 2017, 3, .	0.2	5
574	Statin Drug Interactions in Patients with Comorbidities and on Multiple Medications. US Endocrinology, 2012, 08, 104.	0.3	2
575	Statin-Associated Muscle Adverse Events: Update for clinicians. Sultan Qaboos University Medical Journal, 2016, 16, e406-415.	0.3	10
576	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2020, 9, 2521-2534.	1.3	15
577	In-Silico Modeling in Drug Metabolism and Interaction: Current Strategies of Lead Discovery. Current Pharmaceutical Design, 2019, 25, 3292-3305.	0.9	14
578	Statins and the Brain: More than Lipid Lowering Agents?. Current Neuropharmacology, 2018, 17, 59-83.	1.4	71
579	Is there is Need for Ubiquinone (CoQ10) Supplementation in Statin- Associated Myopathy?. The Open Nutraceuticals Journal, 2010, 3, 242-247.	0.2	2
580	Common Adverse Drug-Drug Interactions in Dermatology: Oral Therapies. SKIN the Journal of Cutaneous Medicine, 2017, 1, 74-82.	0.1	1
581	Conservative treatment of lamivudine-induced rhabdomyolysis in a patient with acute exacerbation of chronic hepatitis B. Acta Hepatologica Japonica, 2015, 56, 341-347.	0.0	1
582	Efficacy of Pravastatin in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and Protease Inhibitor (PI)-based HAART in HIV-Infected Patients. American Journal of Infectious Diseases, 2008, 4, 124-130.	0.1	3
583	Selective Serotonin Reuptake Inhibitor Drug Interactions in Patients Receiving Statins. Journal of Clinical Psychiatry, 2014, 75, e95-e99.	1.1	21
584	Management of Diabetes in Organ Transplant Patients. Journal of Korean Diabetes, 2014, 15, 134.	0.1	1
585	Statin intolerance. Journal of Postgraduate Medicine, 2011, 57, 321-328.	0.2	25
586	Bacteriostatic effect of simvastatin on selected oral streptococci in vitro. Contemporary Clinical Dentistry, 2017, 8, 59.	0.2	13
587	Statin Muscle Toxicity and Genetic Risk Factors. International Journal of Genomic Medicine, 2013, 01, .	0.0	4
588	Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 798-802.	0.3	24
589	Pediatric Statin Administration: Navigating a Frontier with Limited Data. Journal of Pediatric Pharmacology and Therapeutics, 2016, 21, 380-403.	0.3	14

#	Article	IF	Citations
590	Evaluation of Sexual Dimorphism in the Efficacy and Safety of Simvastatin/Atorvastatin Therapy in a Southern Brazilian Cohort. Arquivos Brasileiros De Cardiologia, 2014, 103, 33-40.	0.3	14
591	Pharmaceutical Compounds in Aquatic Environmentsâ€"Occurrence, Fate and Bioremediation Prospective. Toxics, 2021, 9, 257.	1.6	52
592	Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 2008, , 1009-1033.		1
594	ï¼"ï¼Žã‚¤ã‚¿ãƒªãƒƒé¡žâ€•Cerivastatinã®æ"é€€ã•ã‚‰å·¦ã¶ã•ã•. Japanese Journal of Clinical Pharmacology and Therapeutics, 2009, 40, 22		
595	A Survey of Clinical Pharmacokinetic Studies of 17 Cardiovascular Drugs in Japanese New Drug Approvals Between 2000 and 2007. Japanese Journal of Clinical Pharmacology and Therapeutics, 2009, 40, 287-293.	0.1	0
596	HIV Infection and Diabetes. , 2010, , 617-642.		0
599	Antifungal Agents. , 2011, , 509-560.		0
600	Disorders of Lipid Metabolism. , 2011, , 1633-1674.		5
603	Comparison of Drug Interactions between Cyclosporine and Rosuvastatin or Pravastatin in Renal Transplant Recipients. Journal of Korean Society of Health-System Pharmacists, 2013, 30, 549-558.	0.1	0
604	Pitavastatin â€" a new inhibitor of the HMG-CoA reductase: peculiarities of clinical pharmacology and perspectives of its usage in treatment of cardiovascular diseases.. Medicni Perspektivi, 2013, 18, 36-44.	0.1	0
605	Effects of Organic Anion Transporting Polypeptide (OATP1B1/SLCO1B1) Genetic Polymorphism on Statin Therapy. Biomedical and Pharmacology Journal, 2013, 6, 429-433.	0.2	0
606	Effects of Natural Products on Pharmacokinetics and Pharmacodynamics of Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 189-211.	0.2	0
607	Pharmacometrics of Hyperlipidemia. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 539-562.	0.2	0
608	INFLUENCE OF POLYMORPHISM OF OATP1B1 TRANSPORTER TO THE PHARMACOKINETICS AND THERAPEUTIC EFFECTS OF STATINS. Siberian Medical Review, 2014, , 15-23.	0.1	0
609	Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease. , 2014, , 129-152.		0
610	Potential Therapeutic Effects of Statins in Alzheimerâ€™s Disease. , 2014, , 2339-2354.		0
611	Lovastatin-Erythromycin induced Myositis: Case Report and Possible Mechanism. Journal of Pharmacy Practice and Community Medicine, 2015, 1, 30-32.	0.1	0
612	Clinical Drug-Drug Interaction Data: Effects of Antiretroviral Agents on Co-administered Drugs. , 2016, , 79-120.		0

#	Article	IF	Citations
613	Statins for All Patients with Hypertensionâ€"It is still not Prime Time!. Hypertension Journal, 2016, 2, 44-50.	0.1	0
614	Correction of Dyslipidemia in Patients with Coronary Heart Disease Combined with Nonalcoholic Fatty Liver Disease. UkraÃ¯nsÊ¹kij Å¾urnal Medicini BÃ¬ologÃ¬Ã¯ Ta Sportu, 2017, 2, 78-82.	0.0	0
616	Interaction Studies between Sitagliptin Phosphate and Atorvastatin Calcium in Streptozotocin Induced Chronic Type II Diabetes Mellitus Rat Model. Pharmatutor, 2018, 6, 45.	0.4	0
617	Liver Enzymes as Biomarkers for Hepatotoxicity of Statins in Patients with Dyslipidemia. IFMBE Proceedings, 2020, , 611-615.	0.2	0
618	Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences, 2021, 22, 11687.	1.8	44
619	Evaluation of the Utility of PXB Chimeric Mice for Predicting Human Liver Partitioning of Hepatic Organic Anion-Transporting Polypeptide Transporter Substrates. Drug Metabolism and Disposition, 2021, 49, 254-264.	1.7	7
620	Systemic Drugs Used inÂDermatology. , 2020, , 177-212.		0
621	CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1323-1338.	1.8	12
622	Republished: An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase. Drug and Therapeutics Bulletin, 2021, 59, 43-47.	0.3	0
625	Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats. Archives of Medical Science, 2012, 8, 549-54.	0.4	4
626	Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian Journal of Medical Research, 2013, 138, 461-91.	0.4	14
627	Effects of prior treatment with simvastatin on skeletal muscle structure and mitochondrial enzyme activities during early phases of sepsis. International Journal of Clinical and Experimental Pathology, 2014, 7, 8356-65.	0.5	4
628	Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?. Hippokratia, 2015, 19, 332-7.	0.3	4
629	A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients. AMIA Summits on Translational Science Proceedings, 2020, 2020, 664-673.	0.4	1
630	Simvastatin profoundly impairs energy metabolism in primary human muscle cells. Endocrine Connections, 2020, 9, 1103-1113.	0.8	0
631	Mechanisms and genetics of drug transport. , 2022, , 213-239.		1
632	Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Cardiac Failure Review, 2021, 7, e15.	1.2	0
633	The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles. Pharmaceutics, 2021, 13, 1961.	2.0	20

#	Article	IF	Citations
634	Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review. European Journal of Pharmacology, 2021, 913, 174590.	1.7	5
635	Drugâ€“Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. Journal of Clinical Pharmacology, 2022, 62, 835-846.	1.0	5
636	ÐŸÐ¸Ñ‚Ð°Ð²Ð°ÑÑ‚Ð°Ñ‚Ð¸Ð½ â€” Ð½Ð¾Ð²Ñ‹Ð¹ Ð¸Ð½Ð³Ð¸Ð±Ð¸Ñ‚Ð¾Ñ€ Ð“Ð¼Ð“-ÐšÐ¾Ð• Ñ€ÐµÐ Ñƒ Ð°Ñ‚Ð·Ð¾Ñ‚ÐµÐ¼Ð¸Ñ‡ÐµÑ	0.0	0
637	Simvastatin profoundly impairs energy metabolism in primary human muscle cells. Endocrine Connections, 2020, 9, 1103-1113.	0.8	5
638	Adverse effects of statin therapy and their treatment. Cardiovascular Prevention and Pharmacotherapy, 2022, 4, 1-6.	0.0	1
639	SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care. Clinical Pharmacology and Therapeutics, 2022, 111, 1075-1083.	2.3	10
640	Experimental and Modeling Evidence Supporting the Trans-Inhibition Mechanism for Preincubation Time-Dependent, Long-Lasting Inhibition of Organic Anion Transporting Polypeptide 1B1 by Cyclosporine A. Drug Metabolism and Disposition, 2022, 50, 541-551.	1.7	12
641	Acute rhabdomyolysis in hepatitis-associated aplastic anemia patient undergoing allogeneic hematopoietic stem-cell transplantation: case report and literature review. European Journal of Medical Research, 2022, 27, 45.	0.9	0
642	Drug Interactions. Medical Clinics of North America, 2022, 106, 389-399.	1.1	1
643	Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents. Drugs and Aging, 2022, 39, 251-256.	1.3	2
644	Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study. BMC Geriatrics, 2022, 22, 242.	1.1	5
647	Prevalence and predictors of clinically significant statinâ€“drug interactions among Yemeni patients taking statins for primary and secondary prevention of cardiovascular disease. Current Medical Research and Opinion, 2022, 38, 889-899.	0.9	1
648	Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. Antiviral Therapy, 2007, 12, 1127-1132.	0.6	64
649	Cyclosporine. , 2013, , 199-211.e2.		4
650	Polygonum Multiflorum Thunb. Induces Hepatotoxicity by Disrupting the Metabolism of Bilirubin and Bile Acid. SSRN Electronic Journal, 0, , .	0.4	0
651	Genomewide Association Study of Simvastatin Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2022, 112, 676-686.	2.3	14
654	Polygonum multiflorum Thunb. Induces hepatotoxicity in SD rats and hepatocyte spheroids by Disrupting the metabolism of bilirubin and bile acid. Journal of Ethnopharmacology, 2022, 296, 115461.	2.0	4
655	Association Between Vitamin D Supplementation and Statin-Associated Muscle Symptoms: A Systematic Review. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 337-351.	1.0	2

#	Article	IF	Citations
656	Development and Validation of the Quantitative Determination of Atorvastatin in HepG2 Cell Line Using High-Performance Liquid Chromatography with Mass-Spectrometric Detection. I P Pavlov Russian Medical Biological Herald, 2022, 30, .	0.2	2
657	Safety of Statins and Nonstatins for Treatment of Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, 51, 655-679.	1.2	7
658	Statin-associated muscle symptoms: Myth or reality?. Revista Clínica Espanõla, 2022, , .	0.3	2
659	A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. British Journal of Clinical Pharmacology, 2023, 89, 242-252.	1.1	15
660	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. Biomedicine and Pharmacotherapy, 2022, 155, 113701.	2.5	3
661	Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. International Journal of Molecular Sciences, 2022, 23, 9986.	1.8	5
662	Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5. Clinical and Translational Science, 2022, 15, 2720-2731.	1.5	5
663	Assessment of potential drugâ€“drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon, 2022, 8, e11278.	1.4	4
664	Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety. Personalized Medicine, 2023, 20, 65-86.	0.8	0
665	The frequency of rs2231142 in ABCG2Âamong Asian subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics, 2023, 24, 15-26.	0.6	4
666	The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder. Current Atherosclerosis Reports, 2023, 25, 43-53.	2.0	0
667	Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review. Plants, 2023, 12, 623.	1.6	2
668	Correlates of Myopathy in Diabetic Patients Taking Statins. Cureus, 2023, , .	0.2	1
669	Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance proteinâ€mediated drug interaction?. British Journal of Clinical Pharmacology, 2023, 89, 2309-2315.	1.1	6
670	Regulatory Effects and Molecular Mechanisms of Tea and Its Active Compounds on Nonalcoholic Fatty Liver Disease. Journal of Agricultural and Food Chemistry, 2023, 71, 3103-3124.	2.4	8
671	Preincubation Time-Dependent, Long-Lasting Inhibition of Drug Transporters and Impact on the Prediction of Drugâ^'Drug Interactions. Drug Metabolism and Disposition, 2023, 51, 1077-1088.	1.7	5
672	Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents. Journal of the American Society of Nephrology: JASN, 2023, 34, 1069-1077.	3.0	5
673	Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drugâ€“Drug Interactions in Rats. Pharmaceutics, 2023, 15, 896.	2.0	1

#	Article	IF	Citations
678	Advances in physiologically based modeling coupled with in vitro-in vivo extrapolation of ADMET: Assessing the impact of genetic variability in hepatic transporters. , 2024, , 159-169.		0
693	Pharmacogenomics in Drug Metabolism Enzymes and Transporters. , 2023, , 1-47.		0